ORNBV Orion Oyj Class B

Orion Corporation has decided on cancellation of shares on the joint account

Orion Corporation has decided on cancellation of shares on the joint account

ORION CORPORATION STOCK EXCHANGE RELEASE 15 JUNE 2020 at 15.45 EEST             

         

Orion Corporation has decided on cancellation of shares on the joint account

The Board of Directors of Orion Corporation has decided on cancellation of 63,650 Orion Corporation A shares and 59,900 Orion Corporation B shares that are on the company’s joint account and which, based on the decision by the Annual General Meeting of Orion Corporation on 6 May 2020 on the forfeiture of the shares in Orion Corporation on the joint account, have been transferred to the company. The share cancellation does not have effect on the company’s share capital. The cancellation of the shares will be notified to the Trade Register and the shares will be canceled when the notification is registered.

The total number of shares in Orion Corporation after the share cancellation will be 141 134 278, of which 35,443,475 are A shares and 105,690,803 are B shares. The total number of votes of the company's shares will be 814,560,303 and Orion will hold 671,082 B shares as treasury shares.



ORION CORPORATION

Timo Lappalainen

President and CEO
  Olli Huotari

SVP, Corporate Functions
 

                                                                                                                                   

Contact person:

Tuukka Hirvonen, Investor Relations

tel. +358 10 426 2721



Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland





Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

EN
15/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

Orion Corporation: Managers’ transactions – Liisa Hurme

Orion Corporation: Managers’ transactions – Liisa Hurme ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET         Orion Corporation: Managers’ transactions – Liisa Hurme Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Liisa HurmePosition: Chief Executive ...

 PRESS RELEASE

Orion Corporation: Managers’ transactions – Julia Macharey

Orion Corporation: Managers’ transactions – Julia Macharey ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET         Orion Corporation: Managers’ transactions – Julia Macharey Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Julia MachareyPosition: Other s...

 PRESS RELEASE

Orion Corporation: Managers’ transactions – Hao Pan

Orion Corporation: Managers’ transactions – Hao Pan ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET         Orion Corporation: Managers’ transactions – Hao Pan Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Hao PanPosition: Other senior managerIssuer: ...

 PRESS RELEASE

Orion Oyj: Johtohenkilöiden liiketoimet – Hao Pan

Orion Oyj: Johtohenkilöiden liiketoimet – Hao Pan ORION OYJ        JOHTOHENKILÖIDEN LIIKETOIMET         10.3.2026 KLO 17.00          Orion Oyj: Johtohenkilöiden liiketoimet – Hao Pan Orion Oyj on saanut seuraavan Markkinoiden väärinkäyttöasetuksen (EU) N:o 596/2014 mukaisen ilmoituksen johtohenkilön tai johtohenkilön lähipiirin liiketoimista Orionin osakkeilla tai muilla Orioniin liittyvillä rahoitusvälineillä. Orion Oyj - Johdon liiketoimet____________________________________________IlmoitusvelvollinenNimi: Hao PanAsema: Muu ylin johtoLiikkeeseenlaskija: Orion OyjLEI: 74370029VAHCXDR7...

 PRESS RELEASE

Orion Corporation: Managers’ transactions – Outi Vaarala

Orion Corporation: Managers’ transactions – Outi Vaarala ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET         Orion Corporation: Managers’ transactions – Outi Vaarala Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Outi VaaralaPosition: Other senior ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch